Education
About Us
Working with TipRanks
Follow Us
Aerovate Therapeutics, Inc. (AVTE)
NASDAQ:AVTE
AVTE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.02 - $884.98
Previous CloseN/A
Volume47.72K
Average Volume (3M)N/A
Market Cap
$325.26M
Enterprise Value-$1.40M
Total Cash (Recent Filing)$87.97M
Total Debt (Recent Filing)$96.70M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
May 19, 2025EPS Estimate
-6.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-59.44
Shares Outstanding32,235,928
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-10.26
Enterprise Value/Gross Profit-26.84
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aerovate Therapeutics News
AVTE FAQ
What was Aerovate Therapeutics, Inc.’s price range in the past 12 months?
Aerovate Therapeutics, Inc. lowest stock price was $9.02 and its highest was $884.98 in the past 12 months.
What is Aerovate Therapeutics, Inc.’s market cap?
Aerovate Therapeutics, Inc.’s market cap is $325.26M.
When is Aerovate Therapeutics, Inc.’s upcoming earnings report date?
Aerovate Therapeutics, Inc.’s upcoming earnings report date is May 19, 2025 which is 85 days ago.
How were Aerovate Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Aerovate Therapeutics, Inc. overvalued?
According to Wall Street analysts Aerovate Therapeutics, Inc.’s price is currently Overvalued.
Does Aerovate Therapeutics, Inc. pay dividends?
Aerovate Therapeutics, Inc. does not currently pay dividends.
What is Aerovate Therapeutics, Inc.’s EPS estimate?
Aerovate Therapeutics, Inc.’s EPS estimate is -6.99.
How many shares outstanding does Aerovate Therapeutics, Inc. have?
Aerovate Therapeutics, Inc. has 32,235,928 shares outstanding.
What happened to Aerovate Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aerovate Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AVTE
Aerovate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 44.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-59.01%
Trailing 12-Months
Asset Growth
-27.42%
Trailing 12-Months
Company Description
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics (AVTE) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Entera Bio
―
Black Diamond Therapeutics
―
Surrozen
―
Elicio Therapeutics
―
Tenaya Therapeutics
―
Ownership Overview
51.18% Insiders
4.89% Mutual Funds
0.26% Other Institutional Investors
38.77% Public Companies and
Individual Investors